Novartis' neuroscience disease area is seeking a data scientist or computational biologist to develop novel approaches in genetic medicine to address medical challenges and improve patient outcomes by integrating, analyzing, and interpreting large biomedical datasets.
Requirements
- Experience in programming with Python and/or R
- Experience in processing and analyzing proteomics (Somascan, Olink, MS-based, or similar)
- Solid understanding or pathways, systems biology, biological networks
- Experience in cellular / molecular biology
- Ability to understand inter-species variations
- Experience in analyzing transcriptomics (bulk, single cell, spatial), knowledge of splicing
- Experience with experimental design
Responsibilities
- Applying established and novel approaches to model multi-modal clinical or pre-clinical data to identify biomarkers predictive of disease progression and treatment response, and to nominate novel therapeutic target hypotheses
- Work with wet lab scientists to develop testable biological hypotheses and collaborate in designing rigorous preclinical experiments
- Collaborate with other data scientists and be a subject matter expert in analyzing data from tissue and biofluids
- Analyze proteomics, transcriptomics or related data from clinical, in-vivo or in-vitro studies
Other
- Senior Expert I: Ph.D. with 2 or more years of experience (ideally in industry) in computational biology, genomics, biological sequence design, or related fields. Senior Expert II 3+ years of industry experience in computational biology, genomics biological sequence design or related fields.
- Experience in neuroscience is highly preferred
- LI-Hybrid
- The final salary offered is determined based on factors like, but not limited to, relevant skills and experience, and upon joining Novartis will be reviewed periodically. Novartis may change the published salary range based on company and market factors.
- Your compensation will include a performance-based cash incentive and, depending on the level of the role, eligibility to be considered for annual equity awards.
